MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2478/enr-2018-0005

Медицинская библиотека · Endocrine regulations · 2018

A short review of primary aldosteronism in a question and answer fashion.

Farrugia Frederick-Anthony, Zavras Nicolaos, Martikos Georgios, Tzanetis Panagiotis, Charalampopoulos Anestis, Misiakos Evangelos P, Sotiropoulos Dimitrios, Koliakos Nikolaos

СтатьяОбзорПеревод в очереди

Аннотация

OBJECTIVES

The aim of this study was to present up to date information concerning the diagnosis and treatment of primary aldosteronism (PA). PA is the most common cause of endocrine hypertension. It has been reported up to 24% of selective referred hypertensive patients.

METHODS

We did a search in Pub-Med and Google Scholar using the terms: PA, hyperaldosteronism, idiopathic adrenal hyperplasia, diagnosis of PA, mineralocorticoid receptor antagonists, adrenalectomy, and surgery. We also did cross-referencing search with the above terms. We had divided our study into five sections: Introduction, Diagnosis, Genetics, Treatment, and Conclusions. We present our results in a question and answer fashion in order to make reading more interesting.

RESULTS

PA should be searched in all high-risk populations. The gold standard for diagnosis PA is the plasma aldosterone/plasma renin ratio (ARR). If this test is positive, then we proceed with one of the four confirmatory tests. If positive, then we proceed with a localizing technique like adrenal vein sampling (AVS) and CT scan. If the lesion is unilateral, after proper preoperative preparation, we proceed, in adrenalectomy. If the lesion is bilateral or the patient refuses or is not fit for surgery, we treat them with mineralocorticoid receptor antagonists, usually spironolactone.

CONCLUSIONS

Primary aldosteronism is the most common and a treatable case of secondary hypertension. Only patients with unilateral adrenal diseases are eligible for surgery, while patients with bilateral and non-surgically correctable PA are usually treated by mineralocorticoid receptor antagonist (MRA). Thus, the distinction between unilateral and bilateral aldosterone hypersecretion is crucial.

Для цитирования: Farrugia Frederick-Anthony, Zavras Nicolaos, Martikos Georgios, Tzanetis Panagiotis, Charalampopoulos Anestis, Misiakos Evangelos P, Sotiropoulos Dimitrios, Koliakos Nikolaos. A short review of primary aldosteronism in a question and answer fashion.. Endocrine regulations. 2018. DOI: 10.2478/enr-2018-0005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.